Institute of Human Virology 725 W Lombard St. N151 Baltimore, MD 21201
Education and Training
2005 B.S., Psychobiology, University of California, Los Angeles (Cum Laude)
2009 M.D., Feinberg School of Medicine, Northwestern University
2009 M.P.H., Feinberg School of Medicine, Northwestern University
POST GRADUATE EDUCATION AND TRAINING
2009-2010 Internship, University of Maryland Medical Center
2010-2012 Residency, Internal Medicine, University of Maryland Medical Center
2012-2014 Fellowship, Infectious Diseases, University of Maryland Medical Center
2014-2015 Advanced Training, Infectious Diseases in Immunocompromised Hosts, University of Maryland School of Medicine (not ACGME accredited)
Since completing my clinical fellowship in 2014, I have developed expertise in the area of HIV and transplantation. I have developed a cohort of HIV-infected patients both pre- and post- kidney transplantation and developed a database to follow patients after transplant and monitor outcomes. Using this database, our group has looked at the rates of rejection and infection in renal transplant recipients based on the type of induction therapy received as well as outcomes based on the type of HIV regimen the patients received. More recently, my research has focused on looking at factors that may predict individual patients likelihood for rejection prior to transplantation, which led me to look at patient characteristics such as how long patients have been suppressed prior to transplant as a risk factor for rejection, a factor which had not been well explored previously.
In translating my experience with HIV in transplant recipients, I have also started a clinic to evaluate and treat hepatitis C infected renal transplant patients. Given my unique access to this cohort, I have successfully competed for investigator-initiated, industry-sponsored funding to further look at any differences in the immunologic response to hepatitis C treatment in immunosuppressed patients compared to immunocompetent patients.
It is my access to these unique cohorts of patients that will allow me to successfully recruit the necessary patients to help make this research project and collaboration successful.
Transplant and HIV, Transplant and HCV
Husson J, Stafford K, Bromberg J, Haririan A, Sparkes T, Davis C, Redfield R, Amoroso A. Association between duration of HIV-1 viral suppression prior to renal transplantation and acute cellular rejection. Am J Transplant 2017; 17:551-556.
Ongoing Research Support
Merck, Investigator Initiated Grant Husson (PI) 3/2017-Present
Host mechanisms involved in achieving SVR using a fixed dose combination of grazoprevir and elbasvir in treatment of chronic hepatitis C genotype 1 in non-cirrhotic patients with chronic kidney disease before and after renal transplantation.
The goal of this study is to compare immunologic mechanisms in achieving SVR in HCV infected patients before or after kidney transplantation.
Merck, Sponsored Study Husson (PI) 9/2017-Present
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbufir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection
The goal of this study is to evaluate the safety and efficacy of a new fixed dose treatment regimen for HCV genotype 3 infection. We are participating as one of a number of sites in this multicenter study.
Role: Site PI